Back to results
US 2016/0095889 A1Published application
Composition and use of lactobacillus reuteri gmnl-263 in decreasing blood lipid levels
AssigneeGenMont Biotech Inc.
InventorsYI-HSING CHEN, YA-HUI CHEN, TZU-CHI LOU, TING-YUN SHEN
Life of this patent
Estimating the term…
Abstract
A use of a Lactobacillus reuteri GMNL-263 in decreasing blood lipid levels is disclosed. Lactobacillus reuteri GMNL-263 (accession No.: CCTCC M 209263) specifically inhibits gene expression related to pro-inflammatory factor and lipid synthesis and promotes gene expression related to cholesterol metabolism. Lactobacillus reuteri GMNL-263 is utilized to produce a composition for decreasing blood lipid levels, thereby achieving the aim of hyperlipidemia treatment.
Claims17
A probiotics composition for decreasing blood lipid levels, comprising:
- a therapeutically effective amount of Lactobacillus reuteri GMNL-263 (deposited at the China Center for Type Culture Collection of Wuhan University in China under accession No.:
- CCTCC M 209263) to specifically inhibit gene expression related to pro-inflammatory factor and lipid synthesis and to promote gene expression related to cholesterol metabolism, achieving the aim of decrease of blood lipid levels.
A method for decreasing blood lipid levels, comprising:
- administrating a therapeutically effective amount of Lactobacillus reuteri GMNL-263 (deposited at the China Center for Type Culture Collection of Wuhan University in China under accession No.:
- CCTCC M 209263) to specifically inhibit gene expression related to pro-inflammatory factor and lipid synthesis and to promote gene expression related to cholesterol metabolism.
Dependencies are inferred from the claim text.